Cardiac Arrest Treatment Market Report Scope & Overview:

The Cardiac Arrest Treatment Market was valued at USD 5.42 Billion in 2025 and is expected to reach USD 8.40 Billion by 2035, growing at a CAGR of 4.48% from 2026-2035.

The Cardiac Arrest Treatment Market is growing due to the increasing incidence of sudden cardiac arrest cases in elderly patients around the world, increased public access to defibrillators, and technological innovations in miniaturized extracorporeal and implantable devices. There is an increasing tendency towards the development of an integrated ecosystem of devices with monitoring and prediction software together with therapeutic device delivery in healthcare facilities. In addition, there is ongoing development of artificial intelligence algorithms of rhythm prediction, portable hypothermia treatment devices, and new classes of anti-arrhythmia drugs.

In March 2026, Medtronic plc received FDA approval for its OmniaSecure defibrillation lead for conduction system pacing, extending use into left bundle branch area applications. The expanded indication supports the growing shift toward physiologic pacing, broadens Medtronic’s addressable implant base, and aligns with evolving treatment approaches favoring conduction-system-based therapy.

Cardiac Arrest Treatment Market Trends

• Rising adoption of AI-enabled rhythm-prediction tools integrated into emergency medical service dispatch workflows.

• Growing deployment of miniaturized, field-deployable extracorporeal membrane oxygenation systems for refractory arrest.

• Expanding legislative mandates for public-access defibrillator placement in schools, arenas, and transit hubs.

• Increasing use of drone-delivered automated external defibrillators to cut rural emergency response times.

• Rising investment in mRNA-based and RNAi anti-arrhythmic drug pipelines targeting arrhythmogenic pathways.

• Growing adoption of wearable cardioverter defibrillators extending protection through the post-discharge period.

U.S. Cardiac Arrest Treatment Market Outlook

The U.S. Cardiac Arrest Treatment Market was valued at USD 1,890.83 Million in 2025 and is expected to reach USD 2,704.21 Million by 2035, growing at a CAGR of 3.64% from 2026-2035.

The U.S. Cardiac Arrest Treatment Market growth continues to be reinforced by established emergency medical service protocols, widespread automated external defibrillator saturation, and an FDA ecosystem that offers breakthrough device designations for life-saving resuscitation tools. Integrated delivery networks continue to negotiate fleet-wide service contracts for defibrillators and monitoring platforms that sustain predictable replacement cycles and support ongoing equipment availability. Federal liability protections under the Cardiac Arrest Survival Act continue to encourage community responder programs and public-access defibrillator deployment across schools, transit hubs, sports venues, and other high-traffic public locations, strengthening preparedness for emergency cardiac events.

In December 2025, Abbott Laboratories received FDA approval for its Volt Pulsed Field Ablation System to treat atrial fibrillation, strengthening its electrophysiology portfolio. The approval supports integrated arrhythmia management strategies and reflects growing adoption of technologies designed to address high-burden cardiac rhythm disorders while potentially reducing downstream demand for cardiac arrest resuscitation care.

Cardiac Arrest Treatment Market Segment Analysis

• By Product, the Devices segment dominated the Cardiac Arrest Treatment Market with approximately 69.12% share in 2025, and is also the fastest growing with a CAGR of approximately 6.33%.

• By Distribution Channel, the Hospitals segment dominated the Cardiac Arrest Treatment Market with approximately 48.60% share in 2025, while the Online Pharmacies segment is the fastest growing with a CAGR of approximately 6.24%.

• By End User, the Hospitals & Cardiac Centres segment dominated the Cardiac Arrest Treatment Market with approximately 80.73% share in 2025, while the Home & Alternate Care Settings segment is the fastest growing with a CAGR of approximately 5.72%.

By Product, Devices dominates and grows fastest

Devices dominate the Cardiac Arrest Treatment Market in 2025, a position built on technological leaps in AI-driven arrhythmia prediction, miniaturized extracorporeal membrane oxygenation, and modular implantable defibrillation systems that keep pace with evolving resuscitation guidelines. Defibrillators anchor hospital code carts and public-access programs alike, while drone-mounted automated external defibrillators extend emergency-response reach to remote communities that ambulance-based response alone cannot adequately serve. Portable extracorporeal circulatory support platforms are increasingly winning guideline endorsements for refractory cardiac arrest cases, reinforcing device-category demand ahead of pharmacologic alternatives.

This segment also leads on growth, supported by regulatory willingness to fast-track high-impact device technologies and by mechanical circulatory support systems that add incremental hemodynamic stability during and after resuscitation. Manufacturers continue to invest in fault-tolerant battery chemistries, algorithmic risk-scoring software, and low-profile vascular access routes that improve both device reliability and patient outcomes. Health-system consolidation is further accelerating bulk procurement of connected defibrillator fleets, sustaining device-category revenue growth well ahead of the more constrained drug segment.

By Distribution Channel, Hospitals dominate, and Online Pharmacies grow fastest

Hospitals segment will dominate the Cardiac Arrest Treatment Market by 2025, emphasizing the importance of the hospitals as the key source of resuscitation devices and critical care medicines that get stocked, distributed, and delivered in the hospitals within the immediate time of cardiac arrest occurrence. The hospitals sign multi-year purchase agreements on defibrillators, monitoring systems, and pharmaceuticals included in formulary drug list, making them more dominant in the purchase process than retailers and e-commerce. In addition, the growing surgical volumes fuel hospitals' demand for the products.

Online pharmacies are growing fastest, as digital health platforms expand access to maintenance pharmaceuticals for cardiac arrest survivors managing long-term anti-arrhythmic therapy outside acute-care settings. Growing patient comfort with digital prescription fulfillment, combined with expanding insurer support for mail-order pharmacy benefits, is gradually shifting a portion of chronic post-arrest medication management away from traditional retail pharmacy counters and toward more convenient online fulfillment channels.

By End User, Hospitals & Cardiac Centres dominate, and Home & Alternate Care Settings grow fastest

Hospitals and cardiac centers are the dominant segments in 2025, the Cardiac Arrest Treatment Market because of their 24/7 availability of catheterization labs, extracorporeal membrane oxygenation rooms, and large telemetry capabilities that other healthcare facilities lack. The utilization of the protocols of extracorporeal cardiopulmonary resuscitation strengthens the dominance because of the significantly greater success rate of such approach to cardiac arrest treatment compared to resuscitation alone. Consolidations of the healthcare systems facilitate the purchases of connected defibrillators and improve their maintenance.

The Home & alternate care fastest growing segments in the market in 2025 will be the ones related to home and other non-hospital environments. These segments benefit from the utilization of the wearable defibrillators controlled by artificial intelligence that ensures protection for high-risk patients when they are discharged after experiencing a cardiac arrest. Now it is possible to utilize telemedicine to adjust remotely implantable devices that provide additional data on the patient's condition and prevent another cardiac arrest.

Regional Analysis

North America Cardiac Arrest Treatment Market Insights

North America accounted for approximately 41.83% of the Cardiac Arrest Treatment Market in 2025, the largest share among all regions, benefiting from established emergency medical service protocols, widespread automated external defibrillator saturation, and an FDA ecosystem that offers breakthrough device designations for life-saving resuscitation tools. Federal liability shields under the Cardiac Arrest Survival Act nurture community-responder programs, while the American Heart Association's public-health targets continue to push individual states to intensify public-access defibrillator legislation and school- and workplace-based deployment mandates.

Integrated delivery networks across the region negotiate fleet-wide service contracts for defibrillators and monitoring platforms that sustain predictable equipment replacement cycles, while large-scale field trials of drone-delivered automated external defibrillators in rural regions are demonstrating meaningful response-time reductions that materially improve neurological outcomes following out-of-hospital cardiac arrest. Canada and Mexico contribute smaller but stable shares, supported by growing government investment in emergency-care infrastructure and expanding private-hospital adoption of advanced resuscitation equipment.

Europe Cardiac Arrest Treatment Market Insights

Europe delivers steady but comparatively cautious growth under unified medical-device regulations that emphasize clinical-evidence depth ahead of broad market adoption. The region champions clinical quality registries that feed outcome data directly into guideline updates, steering hospitals toward evidence-backed procurement decisions rather than purely price-driven purchasing. Germany's advanced pharmaceutical research infrastructure and established medical-device manufacturing base support its position as the region's leading individual market, while the United Kingdom's National Health Service continues to standardize resuscitation equipment procurement across its hospital trust network.

Pilot drone networks in the Netherlands have achieved sub-five-minute automated external defibrillator delivery to cardiac arrest scenes, prompting European Union funding for cross-border replication studies across additional member states. Budget pressures keep purchasing decisions under health-technology assessment review throughout much of the region, yet outcome-based procurement models increasingly reward platforms that demonstrate clear reductions in out-of-hospital mortality. France, Italy, and Spain continue to modernize emergency-care infrastructure under national healthcare-investment programs, while Russia and other Eastern European markets are expected to adopt advanced resuscitation technologies at a comparatively slower pace.

Asia Pacific Cardiac Arrest Treatment Market Insights

Asia Pacific is the fastest-growing region in the Cardiac Arrest Treatment Market, projected to expand at a CAGR of approximately 7.55% from 2026 to 2035, chiefly due to rising cardiovascular mortality and expanded emergency-care funding across densely populated urban provinces in China and India. Domestic manufacturers from China and Japan continue to increase exports of cost-effective automated external defibrillators, challenging Western incumbents on price while meeting International Electrotechnical Commission standards that support broader regional and export-market acceptance.

Fragmented reimbursement landscapes across much of the region still slow uptake of high-ticket extracorporeal membrane oxygenation and conduction-system pacing devices, keeping the market share for expensive capital equipment comparatively modest relative to North America and Europe. Multilateral regulatory harmonization projects, including the Asian Harmonisation Working Party, aim to trim approval timelines by synchronizing dossier requirements, a factor that is gradually reducing entry hurdles for global device brands across South Korea, Australia, and the broader Southeast Asian market.

MEA & Latin America Cardiac Arrest Treatment Market Insights

The Middle East & Africa region represents a smaller but strategically developing share of the Cardiac Arrest Treatment Market, led by GCC countries such as Saudi Arabia and the United Arab Emirates, where government investment in private hospital infrastructure and emergency-care modernization has driven steady adoption of advanced resuscitation equipment. South Africa anchors demand across the broader African continent through a comparatively developed private healthcare sector, while high capital costs and reimbursement gaps continue to restrict broader access to premium defibrillation and circulatory support technologies across much of Sub-Saharan Africa.

Latin America is expanding as public and private healthcare networks in Brazil and Argentina invest in emergency cardiac care infrastructure to address rising cardiovascular disease prevalence across the region. Brazil represents the largest individual market in the region, with major hospital groups standardizing resuscitation equipment procurement across multi-site operations, while budget constraints in public health systems elsewhere in the region continue to favor lower-cost defibrillation technologies and generic anti-arrhythmic pharmaceuticals over premium device and drug alternatives.

Market Dynamics

Growth Drivers: Rising Sudden Cardiac Arrest Burden and Ageing Populations

Growth in the Cardiac Arrest Treatment Market is primarily attributed to population ageing, which increases sudden cardiac death incidence, particularly among adults over 65 years of age. Survival following out-of-hospital cardiac arrest remains persistently low across major markets, and public-health impact goals targeting substantially higher bystander CPR and automated external defibrillator use before emergency medical service arrival continue to push health systems toward procuring integrated device ecosystems rather than one-off equipment purchases. Growing recognition of viral-related myocardial micro-scarring in younger age groups is further broadening the addressable patient population beyond traditional at-risk demographics.

State-mandated automated external defibrillator deployment in schools, sports arenas, and transit hubs continues to expand device density and improve lay-rescuer readiness across multiple jurisdictions, with standardized implementation toolkits helping facility managers navigate procurement and maintenance requirements. Device miniaturization is simultaneously reducing implant risk and opening rhythm-management therapy to moderately at-risk patient cohorts that previously fell outside standard treatment criteria, while extracorporeal cardiopulmonary resuscitation continues to demonstrate markedly higher survival rates for refractory cases compared with conventional resuscitation approaches alone.

Restraints: Product Recalls and High Capital Costs in Emerging Markets

Product recalls and device-related adverse events represent a significant restraint on the Cardiac Arrest Treatment Market, as quality lapses reduce clinician confidence, delay new-product clearances, and push manufacturers to allocate larger budgets toward post-market surveillance rather than new product development. Regulatory agencies have responded with accelerated public safety alert programs for cardiovascular implants following recent Class I recalls, adding compliance costs across the industry even as these measures work to restore longer-term clinician and patient confidence in resuscitation device categories.

High capital costs and reimbursement gaps in emerging markets present a further restraint, as advanced defibrillators and extracorporeal membrane oxygenation circuits command premium pricing that many public healthcare systems in developing economies cannot adequately reimburse beyond basic resuscitation supplies. Heavy reliance on imported devices in several large emerging markets creates additional affordability barriers for public hospitals, while variable clinical-evidence requirements across regulators continue to lengthen approval timelines and add financing pressure on smaller device exporters seeking market entry.

Opportunities: Connected Resuscitation Ecosystems and Precision Temperature Management

Connected, workflow-integrated resuscitation ecosystems that link public-access defibrillation, emergency medical service dispatch, and hospital post-arrest care pathways represent a substantial emerging opportunity within the Cardiac Arrest Treatment Market. Regulatory acceptance of connected automated external defibrillator platforms that incorporate device readiness and event data into broader emergency response systems supports continued vendor investment in analytics-enabled, subscription-supported device ecosystems that extend value well beyond the initial hardware sale.

Post-cardiac arrest neuroprotection and precision temperature management represent a second significant opportunity area, as clinical evidence moves beyond one-size-fits-all therapeutic hypothermia toward more individualized cooling protocols. Early pilot results evaluating portable, on-scene selective brain cooling technologies, combined with comparative evidence suggesting intravascular cooling devices can achieve tighter temperature control than surface-cooling approaches, point toward a meaningful expansion opportunity for vendors that integrate predictive decision support with monitoring and therapy delivery across both emergency medical service and hospital settings.

Recent Developments:

• 2026, Koninklijke Philips N.V. launched Bridge Plus Occlusion Balloon in the U.S., supporting management of superior vena cava tears during cardiac lead extraction.

• 2025, Boston Scientific acquired Bolt Medical for approximately USD 664 million, adding intravascular lithotripsy capabilities and expanding its structural-heart procedural portfolio and offerings.

• 2025, Element Science received FDA premarket approval for Jewel Patch wearable cardioverter defibrillator, following CE Mark and UKCA marking secured in January 2024.

• 2025, Neurescue received CE Mark approval for NEURESCUE, a specialized device designed to manage non-shockable cardiac arrest rhythms beyond defibrillation therapy and tools.

• 2026, FDA accepted HeartHero's premarket approval application for Elliot connected automated external defibrillator, supporting continued investment in connected emergency response technologies and platforms.

Cardiac Arrest Treatment Market Key Players

• Medtronic plc

• Boston Scientific Corporation

• Koninklijke Philips N.V.

• Abbott Laboratories

• Novartis AG

• ZOLL Medical Corporation

• Stryker Corporation

• Nihon Kohden Corporation

• BIOTRONIK SE & Co. KG

• GE HealthCare Technologies Inc.

• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

• MicroPort Scientific Corporation

• LivaNova PLC

• Abiomed, Inc.

• Getinge AB

• Edwards Lifesciences Corporation

• Masimo Corporation

• Amphastar Pharmaceuticals, Inc.

• Adamis Pharmaceuticals Corporation

• Teleflex Incorporated

Cardiac Arrest Treatment Market Report Scope: